Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
- Bedke J.
- Albiges L.
- Capitanio U.
- Giles R. H.
- Hora M.
- Lam T. B.
- Ljungberg B.
- Marconi L.
- Klatte T.
- Volpe A.
- Abu-Ghanem Y.
- Dabestani S.
- Fernandez-Pello S.
- Hofmann F.
- Kuusk T.
- Tahbaz R.
- Powles T.
- Bex A.
Publication date
January 2021
DOIAbstract
Longer follow-up data and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. A recent update of Keynote-426 demonstrated an ongoing overall survival benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a progression-free survival benefit seen across all International Metastatic RCC Database Consortium (IMDC) subgroups. The RCC Guidelines Panel continues to recommend this combination across IMDC risk groups in advanced first-line RCC
Add to ORKG